Acitretin
Keratolytic Agents
Etretinate
Keratin-10
PUVA Therapy
Psoriasis
Update on psoriasis therapy: a perspective from the USA. (1/54)
Because physicians from different nations frequently acquire the use of a new medication at different times, the international exchange of experiences with the new medication is valuable in maximizing its efficacy worldwide. In recent years, many new therapeutic agents have been approved for treating psoriasis in the United States. These include the topical agent calcipotriol and the systemic agents acitretin and cyclosporine. In addition to new agents, a new therapeutic paradigm, sequential therapy, has been introduced recently. It is the hope of the authors that by sharing this paradigm and experiences with these agents in the United States, dermatologists in Japan may gain further insight into optimizing the use of these agents in the treatment of psoriasis. (+info)Lichen planus. (2/54)
Lichen planus is an inflammatory mucocutaneous condition with characteristic violaceous polygonal flat-topped papules and plaques. Pruritus is often severe. Skin lesions may be disfiguring, and involvement of the oral mucosa or genital mucosa in severe cases may be debilitating. Oral lichen planus may predispose to the development of squamous cell carcinoma within lesions. Involvement of the scalp and the nails may also occur. While most cases of lichen planus are idiopathic, some may be caused by the ingestion of certain medications (e.g., gold, antimalarial agents, penicillamine, thiazide diuretics, beta blockers, nonsteroidal anti-inflammatory drugs, quinidine and angiotensin-converting enzyme inhibitors) or linked to hepatitis C virus infection. Patients with localized lichen planus are usually treated with potent topical steroids, while systemic steroids are used to treat patients with generalized lichen planus. (+info)Efficacy of acitretin in severe psoriasis. (3/54)
Acitretin (Soriatane, Roche Pharmaceuticals) is an aromatic retinoid, effective in the treatment of severe psoriasis. This study highlights data from two existing clinical trials to capture PASI 50 and PASI 75 responder rates which represent a common metric used in current psoriasis clinical trials. A review of pharmacokinetics, safety and a discussion of relapse rate establish acitretin as an efficacious, convenient, oral treatment for initial and maintenance therapy of severe psoriasis. (+info)Pityriasis rubra pilaris. (4/54)
Pityriasis rubra pilaris is a chronic, papulosquamous dermatosis of unclear etiology. The case of a 61-year-old man with pityriasis rubra pilaris is presented. The clinical forms, histopathologic features, and treatment options of pityriasis rubra pilaris are reviewed. (+info)The distribution of cis- and trans-acitretin in human epidermis. (5/54)
The concentrations of trans-acitretin and its principal metabolite, cis-acitretin, were measured by h.p.l.c. after single and multiple dosing (50 mg orally for 13 days) in plasma, blister fluid and epidermal samples from four healthy male volunteers. Within-day epidermal concentrations of trans-acitretin exceeded those of the cis-form which were at the limit of assay sensitivity. No accumulation of trans-acitretin was observed in plasma or blister fluid but AUC values for the drug in blister roof cells tended to be higher after multiple dosing. (+info)Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. (6/54)
Recent data indicate that isomerisation to all-trans retinoic acid (ATRA) is the key mechanism underlying the favourable clinical properties of 13-cis retinoic acid (13cisRA) in the treatment of neuroblastoma. Retinoic acid (RA) metabolism is thought to contribute to resistance, and strategies to modulate this may increase the clinical efficacy of 13cisRA. The aim of this study was to test the hypothesis that retinoids, such as acitretin, which bind preferentially to cellular retinoic acid binding proteins (CRABPs), or specific inhibitors of the RA hydroxylase CYP26, such as R116010, can increase the intracellular availability of ATRA. Incubation of SH-SY5Y cells with acitretin (50 microM) or R116010 (1 or 10 microM) in combination with either 10 microM ATRA or 13cisRA induced a selective increase in intracellular levels of ATRA, while 13cisRA levels were unaffected. CRABP was induced in SH-SY5Y cells in response to RA. In contrast, acitretin had no significant effect on intracellular retinoid concentrations in those neuroblastoma cell lines that showed little or no induction of CRABP after RA treatment. Both ATRA and 13cisRA dramatically induced the expression of CYP26A1 in SH-SY5Y cells, and treatment with R116010, but not acitretin, potentiated the RA-induced expression of a reporter gene and CYP26A1. The response of neuroblastoma cells to R116010 was consistent with inhibition of CYP26, indicating that inhibition of RA metabolism may further optimise retinoid treatment in neuroblastoma. (+info)Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. (7/54)
OBJECTIVE: In vitro and in vivo models indicate that all-trans retinoic acids influence glucose and lipid metabolism. We aimed to evaluate the effects of chronic treatment with acitretin, an all-trans retinoic acid, on glucose metabolism, lipid profile and adiponectin and resistin levels. DESIGN: Ten normoglycemic, normolipemic patients affected with psoriasis vulgaris were studied before and after 1 and 3 months of oral treatment with 35 microg of acitretin. METHODS: Glucose metabolism, lipid profile, and adiponectin and resistin levels were evaluated in basal conditions and after acitretin treatment. Ten healthy subjects matched for age, body mass index (BMI) and insulin sensitivity were studied as controls. RESULTS: One-month acitretin treatment reduced psoriasis activity, insulin sensitivity, evaluated as QUICKI values (0.364 +/- 0.034 versus 0.329 +/- 0.051; P < 0.05) and HOMA-IR index (1.53 +/- 0.73 versus 2.59 +/- 1.41; P < 0.05), and high-density lipoprotein (HDL)-cholesterol levels (45.2 +/- 11.7 versus 39.4 +/- 10.4 mg/dl; P = 0.01). The impairment in glucose and lipid homeostasis was transient and not associated to BMI variations. Adiponectin levels did not change during the treatment, while resistin levels, which were higher in untreated patients than in controls (9.4 +/- 4.4 versus 6.2 +/- 2.1 ng/ml; P = 0.05), fell within the normal range after 1 and 3 months of therapy. The normalization of resistin levels occurred without significant changes in circulating tumor necrosis factor alpha (TNFalpha) levels, which persisted elevated throughout the treatment. CONCLUSIONS: Treatment with a low dose of acitretin induced a mild, transient reduction of insulin sensitivity and HDL-cholesterol levels that was not related to modifications of adiponectin, resistin and TNFalpha levels. Although the role of resistin in humans remains elusive, the levels of this adipocytokine seem to be affected, at least in part, by retinoids. (+info)Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. (8/54)
Vascular endothelial growth factor (VEGF) promotes angiogenesis, and elevated levels are found in plaques of psoriasis. Two VEGF polymorphisms, +405 and -460, are associated with early-onset psoriasis and are close to the functional activator protein-1 site (+419) through which retinoids, an established systemic therapy for psoriasis, can block production of VEGF. We report that peripheral blood mononuclear cells (PBMCs) and epidermal keratinocytes (KC) from patients with psoriasis demonstrate differential, genotype-dependent, regulation of VEGF. For PBMCs, VEGF genotype distinguishes two groups of patients with psoriasis - "high and low VEGF producers" (P < 0.001). In contrast, KC production of VEGF is not genotype dependent. However, the effects of all-trans retinoic acid (RA) on cellular expression of VEGF are determined by both cell type and genotype. RA inhibits KC production of VEGF in a genotype-dependent manner (P < 0.005) whereas RA stimulates PBMCs production irrespective of VEGF genotype (P < 0.001). We also report that the -460 VEGF polymorphism appears to have a clinical pharmacogenetic role in predicting response or non-response of psoriasis to acitretin (P = 0.01). In future, determination of VEGF gene polymorphisms and thus individual patient VEGF "signatures" may be used as a prognostic factor for psoriasis susceptibility/severity and as a means for optimizing treatment response. (+info)Some common types of hand dermatoses include:
1. Contact dermatitis: This is a type of eczema that occurs when the skin comes into contact with an irritant or allergen. It can cause redness, itching, and dryness on the hands.
2. Psoriasis: This is a chronic condition that causes red, scaly patches on the skin. It can affect any part of the body, including the hands.
3. Eczema: This is a general term for a group of conditions that cause dry, itchy skin. It can affect the hands as well as other parts of the body.
4. Dermatitis herpetiformis: This is a condition that causes small blisters or bumps on the skin, often in conjunction with other symptoms such as fever and joint pain.
5. Urticaria: This is a condition that causes hives or itchy, raised welts on the skin. It can be caused by a variety of factors, including allergies, infections, and environmental exposures.
6. Angioedema: This is a condition that causes swelling of the deeper layers of skin, often in conjunction with hives or other symptoms.
7. Necrobiosis lipoidica diabeticorum: This is a condition that affects people with diabetes and causes raised, darkened areas on the skin, often on the hands and feet.
8. Hand eczema: This is a type of eczema that specifically affects the hands, causing dryness, itching, and redness on the palms and soles.
Treatment for hand dermatoses depends on the underlying cause and can include topical creams or ointments, medications, and lifestyle changes such as avoiding irritants and allergens, keeping the hands moisturized, and protecting them from extreme temperatures. In some cases, surgery may be necessary to remove affected skin or repair damaged tissue.
It is important to seek medical attention if you experience any persistent or severe symptoms on your hands, as early diagnosis and treatment can help prevent complications and improve outcomes.
Psoriasis can affect any part of the body, including the scalp, elbows, knees, and lower back. The symptoms of psoriasis can vary in severity, and the condition can have a significant impact on quality of life. In addition to physical discomfort, psoriasis can also cause emotional distress and stigma.
There is no cure for psoriasis, but there are several treatment options available, including topical creams and ointments, light therapy, and systemic medications such as biologic drugs. With proper treatment, many people with psoriasis are able to manage their symptoms and improve their quality of life.
Psoriasis is relatively common, affecting approximately 2-3% of the global population, with a higher prevalence in Caucasians than in other races. It can occur at any age, but typically starts in the late teenage years or early adulthood. Psoriasis is often associated with other health conditions, such as diabetes, heart disease, and depression.
Overall, psoriasis is a complex and multifactorial condition that requires a comprehensive approach to management, including both physical and emotional support. With appropriate treatment and self-care, people with psoriasis can lead full and active lives.
Acitretin
Roche
Psoriasis
Tazarotene
Akhil Maheshwari
Discoid lupus erythematosus
Actinic keratosis
Lichen planus
Vitamin A
Blood donation
Arsenical keratosis
X-linked ichthyosis
Generalized pustular psoriasis
Lichen nitidus
Spiculosis
Etretinate
Psoriatic erythroderma
Minocycline
Pityriasis rubra pilaris
Meleda disease
Haim-Munk syndrome
Chlortetracycline
Diffuse idiopathic skeletal hyperostosis
Epidermolytic hyperkeratosis
Keratoacanthoma
Lidia Rudnicka
ACSL4
Mycosis fungoides
ATC code D05
Epidermodysplasia verruciformis
DailyMed - ACITRETIN capsule
Acitretin
Acitretin: MedlinePlus Drug Information
MedlinePlus - Search Results for: ACITRETIN
Acitretin - PubMed
Acitretin - PubMed
Acitretin - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf
Acitretin dosing, indications, interactions, adverse effects, and more.
Acitretin - Swallowing Difficulties - help and advice for patients and healthcare professionals
DailyMed - ACITRETIN capsule
Acitretin - Superior Toxicology & Wellness
ACITRETIN (AvKARE): FDA Package Insert
Cowden Disease (Multiple Hamartoma Syndrome) Medication: Retinoids
IMSEAR at SEARO: Acitretin induced reversible hyperglycemia.
Acitretin bulk cargo exporter | Acrotac bulk supplier
Acitretin Brand Name Uk The Information Serve Guide This Product | Ezegut
Two for two: Dual therapy with erlotinib and acitretin for twins with severe keratoderma in Olmsted syndrome. | Pediatr...
Subjects: Acitretin -- therapeutic use - Digital Collections - National Library of Medicine Search Results
Effects of Topically Applied Acitretin in Reconstructed Human Epidermis and the Rhino Mouse
Acitretin reverses early functional network degradation in a mouse model of familial Alzheimer's disease
Aviane Advanced Patient Information - Drugs.com
Psoriasis treatment: Oral retinoids
Price list for generic name of drugs | A-Z Index Page
Californian Poppy - Healthy.net
Lichen Amyloidosis Medication: Antihistamines, Topical anti-inflammatory agents
Lichen Amyloidosis Treatment & Management: Approach Considerations, Medical Care, Surgical Care
Biomarkers Search
Vitamin A and its congeners - PubMed
Metabolite of etretinate4
- Acitretin is the main metabolite of etretinate and has demonstrated clinical effects close to those seen with etretinate. (medscape.com)
- Acitretin is the major metabolite of etretinate and is a retinoid used to treat psoriasis. (superiortoxicology.com)
- Acitretin is a synthetic analog of retinoic acid, the main metabolite of etretinate, which has been used to treat psoriasis for years. (superiortoxicology.com)
- Acitretin is a metabolite of etretinate (TEGISON), and major human fetal abnormalities have been reported with the administration of acitretin and etretinate. (medlibrary.org)
Etretinate6
- Ethanol converts acitretin to etretinate, a teratogenic substance that can remain in the body for years. (medscape.com)
- Acitretin is a retinoic acid analog similar to etretinate and isotretinoin. (medscape.com)
- Clinical evidence has shown that concurrent ingestion of acitretin and ethanol has been associated with the formation of etretinate, which has a significantly longer elimination half-life than acitretin. (medlibrary.org)
- Because the longer elimination half-life of etretinate would increase the duration of teratogenic potential for female patients, ethanol must not be ingested by female patients of childbearing potential either during treatment with acitretin or for 2 months after cessation of therapy. (medlibrary.org)
- This allows for elimination of acitretin, thus removing the substrate for transesterification to etretinate. (medlibrary.org)
- The mechanism of the metabolic process for conversion of acitretin to etretinate has not been fully defined. (medlibrary.org)
Treatment with acitretin5
- You must use two acceptable forms of birth control for 1 month before you begin taking acitretin, during your treatment with acitretin, and for 3 years after treatment. (medlineplus.gov)
- You will need to take pregnancy tests regularly during your treatment with acitretin and for at least 3 years after taking acitretin. (medlineplus.gov)
- Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with acitretin and each time you fill your prescription. (medlineplus.gov)
- If the second pregnancy test is negative, initiation of treatment with acitretin should begin within 7 days of the specimen collection. (medlibrary.org)
- Must have a pregnancy test with a sensitivity of at least 25 mIU per mL repeated every month during treatment with acitretin. (medlibrary.org)
Psoriasis6
- Acitretin is used to treat severe psoriasis (abnormal growth of skin cells that causes red, thickened, or scaly skin). (medlineplus.gov)
- Acitretin controls psoriasis but does not cure it. (medlineplus.gov)
- Acitretin inhibits excessive cell growth and keratinization (thickening of skin cells due to protein deposition), and therefore, reduces the thickening of skin, plaque formation, and scaling seen in psoriasis. (superiortoxicology.com)
- Acitretin should be prescribed only by those who have special competence in the diagnosis and treatment of severe psoriasis, are experienced in the use of systemic retinoids, and understand the risk of teratogenicity. (medlibrary.org)
- Acitretin should be considered only for women with severe psoriasis unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments. (medlibrary.org)
- Retinoide oral efectivo en el tratamiento de la psoriasis. (bvsalud.org)
Teratogenic2
- Acitretin is teratogenic in humans and is contraindicated in pregnancy. (superiortoxicology.com)
- Acitretin has been shown to be embryotoxic and/or teratogenic in rabbits, mice, and rats at oral doses of 0.6, 3, and 15 mg per kg, respectively. (medlibrary.org)
Cyclosporine1
- etanercept: 30-60%), whereas outcomes for traditional systemic medications are 30% (acitretin), 60% (methotrexate) and 70% (cyclosporine). (natbiocorp.com)
Methotrexate1
- acitretin, methotrexate. (medscape.com)
Ethanol2
- acitretin, ethanol. (medscape.com)
- Women on acitretin should totally abstain from ethanol during and 2 months after stopping acitretin. (medscape.com)
Medications2
- Do not consume foods, drinks, or prescription or nonprescription medications that contain alcohol while taking acitretin and for 2 months after treatment. (medlineplus.gov)
- Acitretin is in a class of medications called retinoids. (medlineplus.gov)
Fetus2
- Acitretin may harm the fetus. (medlineplus.gov)
- Alcohol and acitretin combine to form a substance that remains in the blood for a long time and can harm the fetus. (medlineplus.gov)
Pregnancy6
- You should not begin taking acitretin until you have taken two pregnancy tests with negative results. (medlineplus.gov)
- Females of reproductive potential must not be given a prescription for acitretin until pregnancy is excluded. (medlibrary.org)
- Must have had 2 negative urine or serum pregnancy tests with a sensitivity of at least 25 mIU per mL before receiving the initial prescription for acitretin. (medlibrary.org)
- The second pregnancy test (a confirmation test) should be done during the first 5 days of the menstrual period immediately preceding the beginning of therapy with acitretin. (medlibrary.org)
- The patient must have a negative result from a urine or serum pregnancy test before receiving a prescription for acitretin. (medlibrary.org)
- For at least 3 years after discontinuing therapy with acitretin, a pregnancy test must be repeated every 3 months. (medlibrary.org)
Oral4
- If you plan to use oral contraceptives (birth control pills) while taking acitretin, tell your doctor the name of the pill you will use. (medlineplus.gov)
- Acitretin interferes with the action of microdosed progestin ('minipill') oral contraceptives. (medlineplus.gov)
- aminolevulinic acid oral, acitretin. (medscape.com)
- Serious - Use Alternative (1) aminolevulinic acid oral, acitretin. (medscape.com)
Mechanism2
- acitretin increases toxicity of omadacycline by Mechanism: unknown. (medscape.com)
- acitretin decreases effects of medroxyprogesterone by unknown mechanism. (medscape.com)
Pregnant3
- Do not take acitretin if you are pregnant or plan to become pregnant within the next 3 years. (medlineplus.gov)
- Stop taking acitretin and call your doctor immediately if you become pregnant, miss a menstrual period, or have sex without using two forms of birth control. (medlineplus.gov)
- Acitretin must not be used by females who are pregnant, or who intend to become pregnant during therapy or at any time for at least 3 years following discontinuation of therapy. (medlibrary.org)
Least 3 years1
- Acitretin also must not be used by females who may not use reliable contraception while undergoing treatment and for at least 3 years following discontinuation of treatment. (medlibrary.org)
Years2
- Do not donate blood while taking acitretin and for 3 years after treatment. (medlineplus.gov)
- Because of the teratogenicity of acitretin, a program called P.P.E.T., P regnancy P revention is E ssential with T reatment, has been developed to educate women of childbearing potential and their healthcare providers about the serious risks associated with acitretin and to help prevent pregnancies from occurring with the use of this drug and for 3 years after its discontinuation. (medlibrary.org)
Major1
- Paternal acitretin exposure and the risk of miscarriage and major congenital malformations: A nationwide register-based cohort study. (bvsalud.org)
Therapy1
- The first test (a screening test) is obtained by the prescriber when the decision is made to pursue therapy with acitretin. (medlibrary.org)
Longer1
- It may take 2-3 months or longer before you feel the full benefit of acitretin. (medlineplus.gov)
Soriatane1
- Tell your doctor if you are taking any of the following medications: acitretin (Soriatane), azathioprine (Imuran), isotretinoin (Accutane), sulfasalazine (Azulfidine), or tretinoin (Vesanoid). (nih.gov)
Retinoids3
- Acitretin is in a class of medications called retinoids. (medlineplus.gov)
- Retinoids such as acitretin can also be used. (nih.gov)
- Acitretin, like many retinoids, can lead to increase in serum aminotransferase levels and has been implicated in cases of acute liver injury which can be severe and even fatal. (nih.gov)
Calcipotriol1
- 19. Acrodermatitis continua of Hallopeau: response to combined treatment with acitretin and calcipotriol ointment. (nih.gov)
Isotretinoin1
- includes pills taken by mouth such as isotretinoin, acitretin , or methotrexate. (nih.gov)
Capsule1
- Acitretin comes as a capsule to take by mouth. (medlineplus.gov)
Systemic1
- Acitretin is a systemic retinoid that is used in dermatology for a variety of conditions. (nih.gov)
Vitamin1
- acitretin increases toxicity of vitamin A by pharmacodynamic synergism. (medscape.com)
Dermatology1
- The British Association of Dermatologists has recently produced comprehensive guidelines on the efficacy and use of acitretin in dermatology. (medscape.com)
Adverse1
- A well-recognized potential adverse event from acitretin is elevated transaminases, indicating acute hepatocyte damage. (nih.gov)
Diseases3
- Acitretin over the last 20 years has proven useful in a number of dermatologic diseases. (medscape.com)
- Acitretin is a synthetic oral retinoid that has been used by dermatologists over the last two decades for a number of cutaneous diseases. (medscape.com)
- [ 1 ] With this recent development, a further examination of acitretin and its therapeutic application in a wide array of cutaneous diseases is warranted. (medscape.com)
Treatment6
- You must use two acceptable forms of birth control for 1 month before you begin taking acitretin, during your treatment with acitretin, and for 3 years after treatment. (medlineplus.gov)
- You will need to take pregnancy tests regularly during your treatment with acitretin and for at least 3 years after taking acitretin. (medlineplus.gov)
- Do not donate blood while taking acitretin and for 3 years after treatment. (medlineplus.gov)
- Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with acitretin and each time you fill your prescription. (medlineplus.gov)
- Acitretin capsules also must not be used by females who may not use reliable contraception while undergoing treatment and for at least 3 years following discontinuation of treatment. (nih.gov)
- 16. Successful treatment of recalcitrant acrodermatitis continua of Hallopeau with adalimumab and acitretin. (nih.gov)
Clinical1
- A literature review demonstrated that most cases of acitretin-induced hepatitis, outside clinical trials, describe patients with a similar mixed hepatitis pattern. (nih.gov)
Successfully1
- 7. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra. (nih.gov)
Mechanism2
- acitretin increases toxicity of omadacycline by Mechanism: unknown. (medscape.com)
- acitretin decreases effects of medroxyprogesterone by unknown mechanism. (medscape.com)
Therapy2
- It has been suggested that acitretin should be a possible first-line therapy in cutaneous lichen planus, particularly in hyperkeratotic form. (medscape.com)
- The first test (a screening test) is obtained by the prescriber when the decision is made to pursue therapy with acitretin capsules. (nih.gov)
Patients5
- In severe lichen planus, improvement was seen in 64% of patients on acitretin (30mg daily) vs. 13% in placebo. (medscape.com)
- 32 In the further open 8 week experiment, 83% of the initial placebo patients subsequently responded to acitretin. (medscape.com)
- In one RCT of 58 patients comparing acitretin 50mg daily for 8 weeks with hydroxychloroquine 400mg daily, researchers found improvement in 46% for acitretin and 50% for hydroxychloroquine. (medscape.com)
- More than half of the patients (14 of 22) on acitretin responded, compared with 6 of 24 in the placebo group. (medscape.com)
- A small amount of acitretin is present in the semen of male patients who take this medication. (medlineplus.gov)
Months1
- It may take 2-3 months or longer before you feel the full benefit of acitretin. (medlineplus.gov)
Increase1
- Your doctor may start you on a low dose of acitretin and gradually increase your dose. (medlineplus.gov)
Type1
- Do not use this type of birth control while taking acitretin. (medlineplus.gov)
Small1
- 35 Data from a small number of randomized controlled trials suggest that acitretin may have a beneficial role in high risk organ transplant recipients. (medscape.com)
Time1
- Take acitretin at around the same time every day. (medlineplus.gov)
Immediately1
- Stop taking acitretin and call your doctor immediately if you become pregnant, miss a menstrual period, or have sex without using two forms of birth control. (medlineplus.gov)